We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+32.61%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$439M
AUM Growth
+$21.9M
Cap. Flow
-$50M
Cap. Flow %
-11.37%
Top 10 Hldgs %
49.48%
Holding
86
New
10
Increased
12
Reduced
30
Closed
14

Top Buys

Rank Stock Value
1
ATRC icon
AtriCure
ATRC
+$4.87M
2
PODD icon
Insulet
PODD
+$2.97M
3
KALV
KalVista Pharmaceuticals
KALV
+$2.75M
4
CATX icon
Perspective Therapeutics
CATX
+$2.65M
5
LRMR icon
Larimar Therapeutics
LRMR
+$2.59M

Top Sells

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$15.2M
2
IMGN
Immunogen Inc
IMGN
+$5.74M
3
SAGE
Sage Therapeutics
SAGE
+$5.31M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$5.25M
5
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$4.9M

Sector Composition

Rank Sector Weight
1 Healthcare 86.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMTX icon
51
Immatics
IMTX
$1.3B
$1.52M 0.35%
145,000
+40,000
+38% +$466K
STIM icon
52
Neuronetics
STIM
$164M
$1.49M 0.34%
313,717
– –
ACET icon
53
Adicet Bio
ACET
$75.6M
$1.41M 0.32%
+37,500
New +$1.55M
AUTL
54
Autolus Therapeutics
AUTL
$548M
$1.38M 0.31%
216,667
+25,597
+13% +$160K
SLRN
55
DELISTED
ACELYRIN
SLRN
$1.37M 0.31%
202,587
-168,613
-45% -$1.28M
ITOS
56
DELISTED
iTeos Therapeutics
ITOS
$1.34M 0.31%
98,560
– –
MLYS icon
57
Mineralys Therapeutics
MLYS
$2.4B
$1.16M 0.26%
90,000
+74,800
+492% +$924K
CGEN icon
58
Compugen
CGEN
$222M
$1.11M 0.25%
430,202
+225,000
+110% +$524K
IMVT icon
59
Immunovant
IMVT
$8.14B
$950K 0.22%
29,416
-11,326
-28% -$413K
ACRV icon
60
Acrivon Therapeutics
ACRV
$74.5M
$939K 0.21%
131,351
– –
APRE icon
61
Aprea Therapeutics
APRE
$8.2M
$918K 0.21%
+137,174
New +$853K
PYPD icon
62
PolyPid
PYPD
$94.5M
$853K 0.19%
+185,446
New +$1.12M
SYRS
63
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$727K 0.17%
135,850
-79,035
-37% -$547K
ADAP
64
DELISTED
Adaptimmune Therapeutics
ADAP
$539K 0.12%
341,064
-10,000
-3% -$12.1K
MASI
65
DELISTED
Masimo
MASI
$441K 0.1%
3,000
– –
NVRO
66
DELISTED
NEVRO CORP.
NVRO
$404K 0.09%
28,000
– –
KPTI icon
67
Karyopharm Therapeutics
KPTI
$45.3M
$291K 0.07%
12,845
– –
VIGL
68
DELISTED
Vigil Neuroscience
VIGL
$245K 0.06%
71,815
– –
CMPX icon
69
Compass Therapeutics
CMPX
$380M
$231K 0.05%
116,882
– –
SPRO icon
70
Spero Therapeutics
SPRO
$72.4M
$215K 0.05%
125,000
– –
ANRO icon
71
Alto Neuroscience
ANRO
$1.11B
$154K 0.03%
+10,000
New +$157K
AMLX icon
72
Amylyx Pharmaceuticals
AMLX
$2.57B
– –
-122,547
Closed -$1.8M
ARGX icon
73
argenx
ARGX
$55.1B
– –
-3,600
Closed -$1.37M
CGEM icon
74
Cullinan Oncology
CGEM
$1.14B
– –
-127,284
Closed -$1.3M
ELEV
75
DELISTED
Elevation Oncology
ELEV
– –
-450,000
Closed -$242K
1 2
3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return
SPT
Siemens Pension Trust Munich Germany, Germany $437M AUM 183.71% 1-Year Est. Return
BCM
Beck Capital Management Austin, Texas $437M AUM 59.35% 1-Year Est. Return

DAFNA Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, DAFNA Capital Management held 86 positions worth $439M, up 5.3% from $417M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

DAFNA Capital Management withdrew a net $50M in Q1 2024, closing 14 positions and reducing 30 holdings. Its most notable exit was Karuna Therapeutics, Inc. Common Stock, an estimated $15.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 85% a quarter earlier.

Against the trend, DAFNA Capital Management opened a new position in Insulet worth $2.73M.

  • DAFNA Capital Management's largest Q1 2024 buy was Insulet: 15,900 shares worth $2.73M.
  • DAFNA Capital Management added most to AtriCure in Q1 2024, an estimated $4.87M increase.
  • DAFNA Capital Management's biggest Q1 2024 reduction was State Street SPDR S&P Biotech ETF, cutting an estimated $4.9M.
  • DAFNA Capital Management fully exited Karuna Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $15.2M.
  • DAFNA Capital Management's ten largest holdings make up 49% of its $439M portfolio in Q1 2024.
  • DAFNA Capital Management opened 10 new positions and closed 14 in Q1 2024.
  • DAFNA Capital Management's portfolio value rose 5.3% quarter-over-quarter to $439M.

Based on DAFNA Capital Management's 13F filing for Q1 2024, filed 15 May 2024.